Home Tags Anti-CD22

Tag: anti-CD22

Catalent’s SMARTag® ADC Stands Out in the Crowd of HER2-targeted Conjugates

The steadily growing number of HER2-targeted antibody-drug conjugates (ADCs) in preclinical development is a testament to the success of the original anti-HER2 ADC, ado-trastuzumab...
Featured Image: Doctor explaining diagnosis to her patient Courtesy: © 2017 Fotolia. Used with permission.

Triphase’s TRPH-222, a Site-specific Anti-CD22 ADC, Enters Clinical Phase I Trials

Triphase Accelerator, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider of advanced...

University of Minnesota Masonic Cancer Center Proceeds With Development Novel Leukemia...

Scientists at the University of Minnesota Masonic Cancer Center have received notification from the U.S. Food and Drug Administration (FDA) that they can proceed...

Polatuzumab Vedotin and Pinatuzumab Vedotin + Rituximab Generally Well-tolerated With Similar...

Updated data on the investigational antibody-drugs conjugates polatuzumab vedotin (anti-CD79b; DCDS4501A) and pinatuzumab vedotin (anti-CD22; DCDT2980S) were presented during the 56th Annual Meeting and...

Anti-CD22 Monomethyl Auristatin Antibody-drug Conjugate Offers Potential Treatment for Non-Hodgkins Lymphoma

Antibody-drug conjugates (ADCs) are target-specific anticancer agents consisting of cytotoxic drugs covalently linked to a monoclonal antibody. They allow specific targeting of drugs to neoplastic...